Nettet26. mai 2024 · Background: Current data shows a median age of diffuse large b-cell lymphoma (DLBCL) diagnosis of 70 years. More than 50% of elderly DLBCL patients can be expected to be cured by modern immunochemotherapy. Survival outcomes in elderly patients with limited stage DLBCL treated with chemotherapy outside of clinical trials … Nettet11. jan. 2024 · The benefit of radiotherapy (RT) after chemotherapy in limited-stage diffuse large B-cell lymphoma (DLBCL) remains controversial. We conducted a …
Role of radiation therapy in primary tonsil large B cell lymphoma: a ...
NettetClinical stage and IPI scores are classical indicators for prognosis estimation in DLBCL patients, 49,50 and the gene mutations have been increasingly recognized to impact prognosis, eg, RAS‐MAPK pathway genes. 51,52 We assessed the impacts of gene mutations in PT-DLBCL, as well as the pairwise mutation patterns. Nettet5. jul. 2016 · Although both S8736 and S0014 were important contributions to limited-stage DLBCL management, follow-up was limited to 5 years at the times of the respective study publications. In a subsequent analysis of S8736 with 10-year follow-up published only in abstract form, 13 the survival curves for CHOP8 and CHOP3RT, surprisingly, … the rookies cast
Primary breast diffuse large B-cell lymphoma in the era of rituximab
Nettet29. jul. 2024 · Patients older than 17 years of age, with no upper age limit with a de novo histological diagnosis of DLBCL, in stages I and II and without risk factors, will be included. All patients will have a baseline PET-CT and will undergo 3 cycles of R-CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone). Nettet14. mar. 2024 · Limited Ann Arbor stage, further chemotherapy following orchiectomy, and low IPI score (less than 2) are correlated with superior survival for DLBCL patients. To retrospectively investigate the clinical characteristics, initial treatment, relapse, therapy outcome, and prognosis of Chinese patients with primary testicular lymphoma (PTL) … NettetConclusion: Primary breast DLBCL appears to be a rare disease. Adding rituximab might improve survival in patients with primary breast DLBCL. Further prospective studies are needed to evaluate the role of rituximab for primary breast DLBCL. Keywords: primary breast lymphoma, diffuse large B-cell lymphoma, rituximab, prognosis track \u0026 field 2022